APC.V - Advanced Proteome Therapeutics Corporation
| Previous Close | 0.1500 |
| Open | 0.1450 |
| Bid | 0.1200 x 0 |
| Ask | 0.1450 x 0 |
| Day's Range | 0.1450 - 0.1450 |
| 52 Week Range | 0.0800 - 0.9000 |
| Volume | 500 |
| Avg. Volume | 13,515 |
| Market Cap | 3.045M |
| Beta (3Y Monthly) | -0.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0020 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.•2 months ago
Does Advanced Proteome Therapeutics Corporation (CVE:APC) Have A High Beta?
Anyone researching Advanced Proteome Therapeutics Corporation (CVE:APC) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are two main...
- GlobeNewswire•7 months ago
Advanced Proteome Therapeutics Reports Positive Results and Advances Collaboration with Heidelberg Pharma
Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (APC.V) (0E8.F), is pleased to announce very positive results from animal studies in collaboration with Heidelberg Pharma. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current treatment strategies and regimens to fight cancer. The combination of APC's proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology, featuring the mushroom toxin amanitin, has led to conjugates that possess high target-specific anti-cancer potency established in several human cancer cell types.
We're sorry this is all we were able to find about this topic.
